

論文 (2013 年以降)

1. Nakashima H, Henmi T, Minami K, Uchida Y, Shiraishi Y, Nunohiro T, Maemura K: Obstructive sleep apnoea increases the incidence of morning peak of onset in acute myocardial infarction. *Eur Heart J Acute Cardiovasc Care.* 2(2): 153-8, 2013.
2. Nakashima H, Umeyama Y, Minami K: Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support. *Am J Case Rep.* 23: 116-119, 2013.
3. Kario K, Ando S, Kido H, Nariyama J, Takiuchi S, Yagi T, Shimizu T, Eguchi K, Ohno M, Kinoshita O, Yamada T, APPENDIX Nunohiro T. The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE. *Journal of Clinical Hypertension* 2013 Feb; 15(2): 133-42.
4. White WB, Cannon CP, Heller SR; EXAMINE Investigators, Collaborators Nunohiro T. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med.* 2013 Oct 3; 369(14): 1327-35.
5. Hokusai-VTE Investigators, Büller HR, Décousus H, Wells P, Collaborators Nunohiro T. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. *N Engl J Med.* 2013 Oct 10; 369(15): 1406-15.
6. Uchida Y, Nakashima H, Takeshita S: Modified mother-child technique using a buddy wire. *J Invasive Cardiol.* 26(5): E52-3, 2014.
7. Pieske B, Butler J, Gheorghide M; SOCRATES Investigators and Coordinators, Collaborators Nunohiro T. Rationale and design of the SOLuble guanylate Cyclase stimulatOR in heArT failurE Studies (SOCRATES). *Eur J Heart Fail.* 2014 Sep; 16(9): 1026-38.
8. Nakashima H, Kurobe M, Minami K, Furudono S, Uchida Y, Amenomori K, Nunohiro T, Takeshita S, Maemura K: Effects of moderate-to-severe obstructive sleep apnea on the clinical manifestations of plaque vulnerability and the progression of coronary atherosclerosis in patients with acute coronary syndrome. *Eur Heart J Acute Cardiovasc Care.*4(1):75-84,2015.
9. Bentley-Lewis R, Aguilar D, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators, Collaborators Nunohiro T. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. *Am Heart J.* 2015 May; 169(5): 631-638.e7.

10. Gheorghide M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators, Collaborators Nakashima H, Nunohiro T, Furudono S. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. *JAMA*. 2015 Dec 1; 314(21): 2251-62.
11. Pfeffer MA, Claggett B, Tardif JC; ELIXA Investigators, Collaborators Nunohiro T. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. *N Engl J Med*. 2015 Dec 3; 373(23): 2247-57.
12. Nakashima H, Mashimo Y, Kurobe M, Muto S, Furudono S, Maemura K: Impact of Morning Onset on the Incidence of Recurrent Acute Coronary Syndrome and Progression of Coronary Atherosclerosis in Acute Myocardial Infarction. *Circ J*. 81(3): 361-367, 2017.
13. Sabatine MS, Giugliano RP, Pedersen TR; FOURIER Steering Committee and Investigators, Collaborators Nunohiro T. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med*. 2017 May 4; 376(18): 1713-1722.
14. Asakura M, Nunohiro T, Kitakaze M: Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction? *Cardiovasc Drugs Ther*. 2017 Aug; 31(4): 401-411.
15. Zannad F, Anker SD, Byra WM; COMMANDER HF Investigators, Collaborators Nunohiro T. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. *N Engl J Med*. 2018 Oct 4; 379(14): 1332-1342.
16. McMurray JJV, Solomon SD, Inzucchi SE, Appendix Nunohiro T. Dapagliflozin in patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019 Nov 21; 381: 1995-2008.
17. Armstrong PW, Pieske B, O'Connor CM; VICTORIA Study Group. Collaborators Nunohiro T. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2020 May 14;382(20):1883-1893.
18. Okumura K, Akao M, Yamashita T; ELDERCARE- AF Committees and Investigators. Collaborators Nunohiro T. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. *N Engl J Med*. 2020 Oct 29;383(18):1735-1745
19. Docherty KF, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Collaborators Nunohiro T. Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. *Diabetes Care*. 2020 Nov;43(11):2878-2881.

20. Lam CSP, Giczevska A, Sliwa K; VICTORIA Study Group. Collaborators Nunohiro T. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. VICTORIA Study Group. Collaborators Nunohiro T. JAMA Cardiol. 2021 Jun 1;6(6):706-712.
21. Docherty KF, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Collaborators Nunohiro T . Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol. 2021 Jul 28. Online ahead of print
22. PCI 時代の急性心筋梗塞患者の来院時血糖値と長期予後の関連 布廣龍也、黒部昌也、中嶋寛 心臓 第 48 号 第 1 号 (2016.1.15)
23. 房室ブロックの心電図を読む 布廣龍也 Heart View Vol.20 No.4: 90-96, 2016
24. 急性心筋梗塞を発症した 2 型糖尿病患者での冠動脈プラーク特性 - 光干渉断層法 (OCT) を用いて - 布廣龍也、古殿真之介、中嶋寛 循環器内科, 81(2): 207-212, 2017
25. 1000 枚見て覚える心電図ギャラリー (電子書籍) 分担執筆 布廣龍也 日本医事新報社 (2018)
26. 215 症例みて覚える心電図ギャラリー (電子書籍) 分担執筆 布廣龍也 日本医事新報社 (2019.1.31)
27. みて覚える心電図ギャラリー 第 19 回布廣龍也 週刊日本医事新報 No.4982 (2019.10.19)
28. 福嶋理知 末永英隆 布廣龍也 前村浩二 右心室ペーシング誘発性心筋症による心不全に対する His 束ペーシングの 1 例 心臓 2020 5 : 52 : 503-509
29. 奈良谷俊 木下和久 布廣龍也 栗山一孝 担癌状態による凝固能亢進が原因と考えられた深部静脈血栓症の 1 症例 医学検査 2021 1 : 70 : 138-143
30. みて覚える心電図ギャラリー 第 68 回 布廣龍也 週刊日本医事新報 No.5059 (2021. 4.10)
31. 急性心筋梗塞患者の高 TG 血症と small dense LDL への影響 布廣龍也 Progress in medicine. 41 : 665-671,2021 7.
32. Liver stiffness assessed by Fibrosis-4 index predicts heart failure in AMI patients
T Nunohiro, K Furukawa, S Kuwasaki, S Kusumoto, S Furudono, M Takeno
European Heart Journal, Volume 43, Issue Supplement 1, February 2022, ehab849.07804
33. みて覚える心電図ギャラリー 第 111 回 布廣龍也 週刊日本医事新法 No.5103 (2022.2.12)